[go: up one dir, main page]

WO2003055558A1 - Polyherbal composition for the treatment of bronchial asthma and the process - Google Patents

Polyherbal composition for the treatment of bronchial asthma and the process Download PDF

Info

Publication number
WO2003055558A1
WO2003055558A1 PCT/IN2002/000041 IN0200041W WO03055558A1 WO 2003055558 A1 WO2003055558 A1 WO 2003055558A1 IN 0200041 W IN0200041 W IN 0200041W WO 03055558 A1 WO03055558 A1 WO 03055558A1
Authority
WO
WIPO (PCT)
Prior art keywords
bud
piper
furiticosa
elettaaria
antidysentercia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2002/000041
Other languages
French (fr)
Inventor
Panchapagesa Muthuswamy Murali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalmia Center for Research and Development
Original Assignee
Dalmia Center for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalmia Center for Research and Development filed Critical Dalmia Center for Research and Development
Priority to AU2002246307A priority Critical patent/AU2002246307A1/en
Publication of WO2003055558A1 publication Critical patent/WO2003055558A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/19Acanthaceae (Acanthus family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/24Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/27Asclepiadaceae (Milkweed family), e.g. hoya
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/51Gentianaceae (Gentian family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/67Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9064Amomum, e.g. round cardamom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Definitions

  • Asthma mer ⁇ s a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role, in particular, mast cells, eosinophils and T. lymphocytes.
  • This inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough, particularly, at night and/ or in the early morning. These episodes are usually associated with widespread but variable air-flow obstruction i.e. often reversible either spontaneously or with treatment and these changes are associated with an increase in the existing bronchial hyper responsiveness to a variety of stimuli
  • Ginger supports a healthy cardiovascular system. Ginger makes blood platelets less sticky and less likely to aggregate.
  • a powerful natural Expectorant used widely in Chinese formulas, for coughs, colds, diarrhea, vomiting, and abdominal pains associated with colds, Edema (stagnation of fluids in lungs) and chronic bronchitis.
  • the dried rhizome of ginger contains approximately 1—4% volatile oils. These are the medically active constituents of ginger, and they are also responsible for ginger characteristic odor and taste.
  • the aromatic principles include zingiberene and bisabolene, while the pungent principles are known as gingerols and shogaols. The pungent constituents are credited with the anti nausea and anti vomiting effects of ginger. Piper Nigrum
  • Piper Longum used in traditional practice to promote respiratory health. It significantly benefited respiratory function and builds up resistance against respiratory tract constriction and inflammation Piper longum also enhances thermogenic response, or release of metabolic heat energy.
  • Elatteria cardamom Elatteria cardamom is a powerful natural anti inflammatory agent and analgesic with significant cardiotonic properties . It heals the inflammation of respiratory tract Cinnamomum cassia Cinnamomum Cassia has been used as a diaphoretic, antipyretic and analgesic . Enhances & eases Expectoration of fluids in Lungs.
  • Adhatoda Vasica is considered in the East to be the best possible treatment for all chest diseases. Used in herbal tobacco to relieve asthma
  • Adhatoda vasica has been traditionally used in the management of allergic disordersand bronchial asthma .
  • Cassia Occidentalis has Powerful Anti microbial and Anti spasmodic activity.
  • the plant contains emodin, physcion, chrysophanol, sitosterol and a xanthone cassiolin
  • Solanum xanthocarpum The plant is employed for cough, asthma and pains in the ches .
  • the plant is also credited with diuretic properties and is used to cure dropsy .
  • Very spiny diffuse herb with blue flowers and yellow, globose berries .
  • Solasonine is present in the fruits.
  • Aegle Marmelos has very powerful Cardiotonic properties strengthens the cardiac muscles and increases the force of contraction and expansion of cardiac muscles
  • this invention provides a synergistic herbal composition for the treatment of bronchial asthma, said composition comprising the following herbs indicated in the proportions given below:
  • Curcuma longa 3.6 % - 4.94 %
  • Holarrhena antidysentercia 3.6 % - 4.94 %
  • the said herbal composition comprises the following herbs by weight %:
  • the said herbal composition comprises the following herbs by weight %>: Achyranthes aspera : 17.33%
  • Zingiber officinal is : 4.32%
  • the said herbal composition comprises the following herbs by weight:
  • Holarrhena antidysentercia 160-300 mg Enicostemma littorale 100-200 mg Calotropis procera 100-200 mg Piper longum 100-200 mg Piper nigrum 350-500 mg Elettaaria Cardamomum 3-12 mg
  • the parts of the herbs used in said composition are:
  • Holarrhena antidysentercia seed
  • Curcuma longa 3.6 % - 4.94 %
  • Holarrhena antidysentercia 3.6 % - 4.94 %
  • the condensation is carried out by using Rotovac vacuum pump at 650 mm pressure and at temperature 45 °C.
  • the extraction of herbs is carried out for a minimum period of 18 hours.
  • Figure 1 is a graph, which illustrates the Peak Expiratory Flow Rate measured in all the patients as shown in Table 1.
  • Figure 2 is a graph, which illustrates the Forced Expiratory Volume in one second measured in all the patients as shown in Table 2.
  • Figure 3 is a graph, which illustrates Forced Vital Capacity of the lung in Liters which measured in all the patients as shown in Table 3 every week
  • Figure 4 is a graph which illustrates the Forced Expiratory Flow Rate 25-75% of the Forced Vital Capacity which measured in all the patients as shown in Table 4 every week.
  • the herbs are mixed in the following proportion by weight for 15 extraction.
  • Curcuma longa 217.6 mg .5 Holarrhena antidysentercia : 217.6 mg
  • DCBT 4567 has demonstrated significant reduction in cough, sputum, rales rhonchi and improves pulmonary functions.
  • the knowledge gained from this study would be of many thousands of subjects, who, like yourself, may suffer from asthma.
  • the period of treatment will be 24 weeks. A total of 7 days grace period is allowed for completion of treatment after first 4 weeks of continuous treatment.
  • the daily dosage is given in Capsules which contains DCBT 4567 herbal drug (1.6 gm) of the herbal extract or Salbutamol (12 mg) or Ragi
  • the trial drugs are administered orally in a capsule with warm water after taking food. All drugs - Herbal, Bio Medical and Placebo - are supplied in capsules of same size, shape, colour and appearance, so that neither the doctor nor the patient is aware of whether an individual patient is prescribed Herbal treatment or Bio Medical treatment or the Placebo.
  • Drugs are packaged separately for each patient and supplied to the investigators.
  • the trial centers supply the drugs to the patients once a week.
  • Peak Expiratory Flow Rate was measured in all of them every week. A 15% improvement in this value since the time the patient entered in the trial was used as an indication for improvement
  • the trial period is only 13 weeks. As the patients and the physicians are comfortable with the trial drugs, the trial period might be extended up to 17 weeks. Total no of patients inducted in the trial 90
  • the Clinical symptoms of Asthma are Dysponea, Wheezing, Cough and Rhonchi.
  • the patients treated with the herbal medicine DCBT have shown significant improvement when treated for Asthma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a synergistic herbal composition for the treatment of bronchial asthma and a process for preparing the same. The said composition comprises the following herbs: Achyranthes aspera, Woodfordia furiticosa, Solanum xanthocarpum, Justicia adhatoda, Acacia arabica Zingiber officinalis, Syzygium aromaticum bud, Curcuma longa, Holarrhena antidysentercia, Enicostemma littorale, Calotropis procera, Piper longum, Piper nigrum and Elettaaria Cardamomum.

Description

POLYHERBAL COMPOSITION FOR THE TREATMENT OF BRONCHIAL ASTHMAAND THE PROCESS
Field of Invention This invention relates to a synergistic herbal composition for the treatment of bronchial Asthma and the process for preparing the same. Background of the invention
Asthma mer~s a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role, in particular, mast cells, eosinophils and T. lymphocytes. This inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough, particularly, at night and/ or in the early morning. These episodes are usually associated with widespread but variable air-flow obstruction i.e. often reversible either spontaneously or with treatment and these changes are associated with an increase in the existing bronchial hyper responsiveness to a variety of stimuli
For unknown reasons, the morbidity and mortality from asthma are increasing in many parts of the world, making it a global health concern. The heterogeneous nature of the clinical manifestations and therapeutic responses of asthma in both adult and pediatric patients indicate that it may be more of a syndrome rather than a specific disease entity. Numerous factors, including viral infections, allergen and irritant exposure, and exercise, among others, complicate both the short- and long-term management of asthma. Therapeutic intervention has focused on the appreciation that airway obstruction in asthma consists of bronchial smooth muscle spasm and variable degrees of airway inflammation characterized by edema, mucous secretion, and the influx of a variety of inflammatory cells. Indigenous and herbal medicines have been in use for many centuries in India for the treatment of bronchial asthma. For instance the following herbs and ingredients have been used either individually or in combination for heeling asthma: Ginger - Zingiber Officinale
Ginger supports a healthy cardiovascular system. Ginger makes blood platelets less sticky and less likely to aggregate. A powerful natural Expectorant, used widely in Chinese formulas, for coughs, colds, diarrhea, vomiting, and abdominal pains associated with colds, Edema (stagnation of fluids in lungs) and chronic bronchitis. The dried rhizome of ginger contains approximately 1—4% volatile oils. These are the medically active constituents of ginger, and they are also responsible for ginger characteristic odor and taste. The aromatic principles include zingiberene and bisabolene, while the pungent principles are known as gingerols and shogaols. The pungent constituents are credited with the anti nausea and anti vomiting effects of ginger. Piper Nigrum
Piper Nigrum acts as a powerful anti convulsant and natural anti inflammation agent. Piper longum
Piper Longum used in traditional practice to promote respiratory health. It significantly benefited respiratory function and builds up resistance against respiratory tract constriction and inflammation Piper longum also enhances thermogenic response, or release of metabolic heat energy. Elatteria cardamom Elatteria cardamom is a powerful natural anti inflammatory agent and analgesic with significant cardiotonic properties . It heals the inflammation of respiratory tract Cinnamomum cassia Cinnamomum Cassia has been used as a diaphoretic, antipyretic and analgesic . Enhances & eases Expectoration of fluids in Lungs. It has powerful anti Ede ic properties - prevention of stagnation of fluids in Lungs It is used as a carminative , purgative and astringent . It is very effective as a cardiac stimulant and diuretic for stimulation of liver i o functions
Adhatoda vasica or Malabar Nut
Adhatoda Vasica is considered in the East to be the best possible treatment for all chest diseases. Used in herbal tobacco to relieve asthma
1 Adhatoda vasica has been traditionally used in the management of allergic disordersand bronchial asthma .
Research performed over the last three decades revealed that the alkaloids present in the leaves, vasicine and vasicinone, possess powerful respiratory stimulant activity . Cassia occidentalis
Cassia Occidentalis has Powerful Anti microbial and Anti spasmodic activity. The plant contains emodin, physcion, chrysophanol, sitosterol and a xanthone cassiolin
Solanum xanthocarpum The plant is employed for cough, asthma and pains in the ches .
The plant is also credited with diuretic properties and is used to cure dropsy . Very spiny diffuse herb with blue flowers and yellow, globose berries . Solasonine is present in the fruits. Solanum indicum
Traditionally used as Indian Ayurvedic Medicine for Asthma , dry & spasmodic cough and chest pains . Aegle marmelos
Aegle Marmelos has very powerful Cardiotonic properties strengthens the cardiac muscles and increases the force of contraction and expansion of cardiac muscles
A number of drugs are available in the market for the treatment of asthma but side effects limit their prolonged use.
Hence there was a need to develop safer alternatives, which is aimed to cure asthma, having a safety profile similar to that of placebo. Yet another object of the present invention is to minimize rather reduce the usage of any steroid drug and to develop an effective herbal composition for the treatment of bronchial asthma.
To achieve the said objective this invention provides a synergistic herbal composition for the treatment of bronchial asthma, said composition comprising the following herbs indicated in the proportions given below:
Ingredients : Proportions ( by wt%
Achyranthes aspera 15.5% - 17.5% Woodfordia furiticosa 1 1.5% - 13.6 % Solanum xanthocarpum 1 1.5 % - 13.6 % Justicia adhatoda 1 1.5 % - 13.6 % Acacia arabica : 1 1.5 % - 13.6 %
Zingiber officinal is : 3.6 % - 4.94%
Syzygium aromaticum bud : 3.6 % - 4.94 %
Curcuma longa : 3.6 % - 4.94 % Holarrhena antidysentercia : 3.6 % - 4.94 %
Enicostemma littorale : 2.22 % - 3.3 %
Calotropis procera : 2.22 % - 3.3 %
Piper longum : 2.22 % - 3.3 %
Piper nigrum : 8.2 % - 7.8 % Elettaaria Cardamomum : 0.06 % - 0.19 %
The said herbal composition comprises the following herbs by weight %:
Achyranthes aspera : 16.62 %
Woodfordia furiticosa : 12.2 % Solanum xanthocarpum : 12.2 %
Justicia adhatoda : 12.2%
Acacia arabica : 12.2%)
Zingiber officinalis : 4.15 %o
Syzygium aromaticum bud : 4.15 % Curcuma longa : 4.15 %)
Holarrhena antidysentercia : 4.15 %o
Enicostemma littorale : 3.17 %o
Calotropis procera : 3.17 %o
Piper longum : 3.17 %) Piper nigrum : 8.33%)
Elettaaria Cardamomum : 0.15 %
The said herbal composition comprises the following herbs by weight %>: Achyranthes aspera : 17.33%
Woodfordia furiticosa : 12.72%
Solanum xanthocarpum : 12.72%
Justicia adhatoda : 12.72%
Acacia arabica : 12.72%
Zingiber officinal is : 4.32%
Syzygium aromaticum bud 4.32%
Curcuma longa : 4.32%
Holarrhena antidysentercia : 4.32%
Enicostemma littorale : 3.30%
Calotropis procera : 3.30%
Piper longum 3.30%
Piper nigrum : 8.70%
Elettaaria Cardamomum : 0.15%
The said herbal composition comprises the following herbs by weight:
Achyranthes aspera : 700-950 mg
Woodfordia furiticosa : 600-700 mg
Solanum xanthocarpum : 600-700 mg
Justicia adhatoda : 600-700 mg
Acacia arabica : 600-700 mg Zingiber officinalis : 160-300 mg
Syzygium aromaticum bud : 160-300 mg
Curcuma longa : 160-300 mg
Holarrhena antidysentercia : 160-300 mg Enicostemma littorale 100-200 mg Calotropis procera 100-200 mg Piper longum 100-200 mg Piper nigrum 350-500 mg Elettaaria Cardamomum 3-12 mg
The parts of the herbs used in said composition are:
Achyranthes aspera : root
Woodfordia furiticosa : flower
Solanum xanthocarpum : fruit
Justicia adhatoda : leaves
Acacia arabica : bark
Zingiber officinalis rhizome
Syzygium aromaticum bud : flower bud
Curcuma longa : rhizome
Holarrhena antidysentercia : seed
Enicostemma littorale : Whole plant
Calotropis procera : root
Piper longum : fruit
Piper nigrum : fruit
Elettaaria Cardamomum : fruit
This invention further provides a process of preparing synergistic herbal composition for the treatment of bronchial Asthma comprising:
shade drying the following herbs, Achyranthes aspera, Woodfordia furiticosa, Solanum xanthocarpum, i Justicia adhatoda, Acacia arabica, Zingiber officinalis, Syzygium aromaticum bud, Curcuma longa, Holarrhena antidysentercia, Enicostemma littorale, Calotropis procera. Piper longum, Piper nigrum and Elettaaria Cardamomum
mixing the said dried herbs in the following proportions to yield the formulation for extraction
Ingredients : Proportions ( by wt%
Achyranthes aspera : 15.5% - 17.5%
Woodfordia furiticosa : 11.5% - 13.6 %
Solanum xanthocarpum : 11.5 % - 13.6 % Justicia adhatoda : 11.5 % - 13.6 %
Acacia arabica : 11.5 % - 13.6 %
Zingiber officinalis : 3.6 % - 4.94%
Syzygium aromaticum bud : 3.6 % - 4.94 %
Curcuma longa : 3.6 % - 4.94 % Holarrhena antidysentercia : 3.6 % - 4.94 %
Enicostemma littorale : 2.22 % - 3.3 %
Calotropis procera : 2.22 % - 3.3 %
Piper longum : 2.22 % - 3.3 %
Piper nigrum : 8.2 % - 7.8 % Elettaaria Cardamomum : 0.06 % - 0. 19 %
racting the said herbs collectively with food, grade alcohol, - filtering the extract,
- condensing the said formulation and drying,
- powdering the dried formulation, sieving, and packing in four capsules to be consumed on a single day.
The said filtration is carried out through cloth followed by Whatman filter paper (no. 1 ) by applying vacuum pressure.
The condensation is carried out by using Rotovac vacuum pump at 650 mm pressure and at temperature 45 °C.
The extraction of herbs is carried out for a minimum period of 18 hours.
The invention will now be described with reference to the accompanying drawings and following examples:
Figure 1 is a graph, which illustrates the Peak Expiratory Flow Rate measured in all the patients as shown in Table 1.
Figure 2 is a graph, which illustrates the Forced Expiratory Volume in one second measured in all the patients as shown in Table 2.
Figure 3 is a graph, which illustrates Forced Vital Capacity of the lung in Liters which measured in all the patients as shown in Table 3 every week Figure 4: is a graph which illustrates the Forced Expiratory Flow Rate 25-75% of the Forced Vital Capacity which measured in all the patients as shown in Table 4 every week.
5 Example 1:
Shade dried or the fresh materials are used for processing depending on the protocol. All herbs were collectively extracted. Extraction of all herbs were carried out with food grade alcohol (70% V/V) in a Soxhlet 10 apparatus for a minimum of 18 hrs. The extracts were filtered through cloth, followed by Whatman filter paper (no. 1 ) by applying vacuum pressure.
The herbs are mixed in the following proportion by weight for 15 extraction.
Achyranthes aspera : 872 mg
Woodfordia furiticosa : 640 mg
Solanum xanthocarpum : 640 mg
20 Justicia adhatoda : 640 mg
Acacia arabica : 640 mg
Zingiber officinalis 217.6 mg
Syzygium aromaticum bud : 217.6 mg
Curcuma longa : 217.6 mg .5 Holarrhena antidysentercia : 217.6 mg
Enicostemma littorale : 166.4 mg
Calotropis procera 166.4 mg
Piper longum : 166.4 mg Piper nigrum : 436.8 mg
Elettaaria Cardamomum : 7.68 ma
After extraction the formulation is further condensed using a Rotovac vacuum pump at 650 mm pressure and at temperature 45°C. Completely dried material is then scrapped, powdered and sieved. The sieved drug is packed in four capsules and given to a patient for single days dosage. This sieved drug is referred to as DCBT 4567.
In-patients with asthma, DCBT 4567 has demonstrated significant reduction in cough, sputum, rales rhonchi and improves pulmonary functions. The knowledge gained from this study would be of many thousands of subjects, who, like yourself, may suffer from asthma.
CLINICAL TRIAL
Patients are allocated in equal proportions to Herbal, Bio Medical or to Placebo series using random sampling numbers.
The period of treatment will be 24 weeks. A total of 7 days grace period is allowed for completion of treatment after first 4 weeks of continuous treatment. The daily dosage is given in Capsules which contains DCBT 4567 herbal drug (1.6 gm) of the herbal extract or Salbutamol (12 mg) or Ragi
2.1 powder (Placebo). The trial drugs are administered orally in a capsule with warm water after taking food. All drugs - Herbal, Bio Medical and Placebo - are supplied in capsules of same size, shape, colour and appearance, so that neither the doctor nor the patient is aware of whether an individual patient is prescribed Herbal treatment or Bio Medical treatment or the Placebo.
Drugs are packaged separately for each patient and supplied to the investigators. The trial centers supply the drugs to the patients once a week.
TRIAL RESULTS
DCBT4567 - ASTHMA - TRIAL RESULTS
Table 1
Figure imgf000014_0001
Peak Expiratory Flow Rate was measured in all of them every week. A 15% improvement in this value since the time the patient entered in the trial was used as an indication for improvement
Table 2
Figure imgf000014_0002
Figure imgf000015_0002
Figure imgf000015_0001
Forced Expiratory Volume in one second was measured in all of them every week. A 15% improvement in this value since the time the patient entered in the trial was used as an indication for improvement.
Table
Figure imgf000015_0003
Forced Vital Capacity of the lung in Liters was measured in all of them every week. A 15% improvement in this value since the time the patient entered in the trial was used as an indication for improvement. Table 4:
Figure imgf000016_0001
Forced Expiratory Flow Rate 25-75% of the Forced Vital Capacity was measured in all of them every week. A 15% improvement in this value since the time the patient entered in the trial was used as an indication for improvement.
ASTHMA TRIAL
Initially, as per the protocol, the trial period is only 13 weeks. As the patients and the physicians are comfortable with the trial drugs, the trial period might be extended up to 17 weeks. Total no of patients inducted in the trial 90
Patients dropped within one week 2
Patients dropped/irregular/no follow up till 13 weeks 6
Patients dropped/irregular/no follow up till 17 weeks 13 CHARACTERISTICS OF PATIENTS ADMITTED
(88 PATIENTS)
Figure imgf000017_0001
IMPROVEMENT IN FEVl/FVC RATIO SHOWN BY THE PATIENTS IN THE TRIAL
Figure imgf000017_0002
Distribution of Patients to Number of Weeks of Additional Drug Intake
Figure imgf000018_0001
It is evident that the herbal composition is very effective in the treatment of Asthma.
Percentage reduction in no. of patients
Figure imgf000019_0001
The Clinical symptoms of Asthma are Dysponea, Wheezing, Cough and Rhonchi. The patients treated with the herbal medicine DCBT have shown significant improvement when treated for Asthma.
Figure imgf000020_0001
DCBT 4567 - COMPLAINTS DURING TREATMENT
Figure imgf000021_0001

Claims

We claim:
1. A synergistic herbal composition for the treatment of bronchial asthma, said composition comprising the following herbs indicated in the proportions given below:
Ingredients Proportions (by wt%) Achyranthes aspera 15.5%- 17.5% Woodfordia furiticosa 11.5%- 13.6% Solanum xanthocarpum 11.5%- 13.6% Justicia adhatoda 11.5%- 13.6% Acacia arabica 11.5%- 13.6% Zingiber officinalis 3.6 % - 4.94% Syzygium aromaticum bud 3.6 % - 4.94 % Curcuma longa 3.6% -4.94% Holarrhena antidysentercia 3.6% -4.94% Enicostemma littorale 2.22 % 1 -I
% Calotropis procera 2.22 % J.J Vo Piper longum 2.22 % - 3.3 % Piper nigrum 8.2 % - 7.8 % Elettaaria Cardamomum 0.06% -0.19%
2. A composition as claimed in claim 1, wherein the following herbs used are the following proportions by weight %:
Achyranthes aspera : 16.62%
Woodfordia furiticosa : 12.2%
Solanum xanthocarpum : 12.2%
Justicia adhatoda : 12.2%
Acacia arabica : 12.2%
Zingiber officinalis : 4.15% Syzygium aromaticum bud 4.15 %
Curcuma longa 4.15 %
Holarrhena antidysentercia 4.15 %
Enicostemma littorale 3.17 %
Calotropis procera 3.17 %
Piper longum 3.17 %
Piper nigrum 8.33%
Elettaaria Cardamomum 0.15 %
10 3. A composition as claimed in claim 1 wherein the following herbs used are the following proportions by weight %:
Achyranthes aspera 17 33%
Woodfordia furiticosa 12 72%
Solanum xanthocarpum 12 72%
15 Justicia adhatoda 12 72%
Acacia arabica 12 72%
Zingiber officinalis 4.32%
Syzygium aromaticum bud 4.32%
Curcuma longa 4.32%
Holarrhena antidysentercia 4.32%
Enicostemma littorale 3.30%
Calotropis procera 3.30%
Piper longum J . 0%
Piper nigrum : 8.70%
T Elettaaria Cardamomum : 0.15%
4. A composition as claimed in claim 1 wherein the following herbs used are the following proportions by weight
"5? Achyranthes aspera : 700-950 mg
Woodfordia furiticosa : 600-700 mg
Solanum xanthocarpum : 600-700 mg
Justicia adhatoda : 600-700 mg Acacia arabica : 600-700 mg
Zingiber officinalis : 160-300 mg
Syzygium aromaticum bud : 160-300 mg
Curcuma longa : 160-300 mg
Holarrhena antidysentercia : 160-300 mg Enicostemma littorale : 100-200 mg.
Calotropis procera : 100-200 mg
Piper longum : 100-200 mg
Piper nigrum : 350-500 mg
Elettaaria Cardamomum : 3-12 mg
5. A composition as claimed in claim 1 wherein the following herbs used are the following proportions by weight
Achyranthes aspera : 872 mg
Woodfordia furiticosa : 640 mg Solanum xanthocarpum : 640 mg
Justicia adhatoda : 640 mg
Acacia arabica : 640 mg
Zingiber officinalis : 217.6 mg
Syzygium aromaticum bud : 217.6 mg Curcuma longa : 217.6 mg
Holarrhena antidysentercia : 217.6 mg
Enicostemma littorale : 166.4 mg
Calotropis procera : 166.4 mg Piper longum : 166.4 mg
Piper nigrum : 436.8 mg
Elettaaria Cardamomum : 7.68 mg
6. A composition as claimed in claim 1 wher ein the parts of the herbs used in said composition are:
Achyranthes aspera : root
Woodfordia furiticosa flower
Solanum xanthocarpum : fruit
Justicia adhatoda leaves
Acacia arabica : bark
Zingiber officinalis : rhizome
Syzygium aromaticum bud : flower bud
Curcuma longa rhizome
Holarrhena antidysentercia : seed
Enicostemma littorale : Whole plant
Calotropis procera : root
Piper longum : fruit
Piper nigrum : fruit
Elettaaria Cardamomum fruit
7. A process of preparing synergistic herbal composition for the treatment of bronchial Asthma as claimed in claim 1 comprising: shade drying the following herbs, Achyranthes aspera, Woodfordia furiticosa, Solanum xanthocarpum. Justicia adhatoda, Acacia arabica, Zingiber officinalis, Syzygium aromaticum bud, Curcuma longa, Holarrhena antidysentercia, Enicostemma littorale, Calotropis procera. Piper longum, Piper nigrum and Elettaaria Cardamomum mixing the said dried herbs in the following proportions to yield the formulation for extraction Ingredients : Proportions (by wt% )
Achyranthes aspera : 15.5% - 17.5%
Woodfordia furiticosa : 11.5% - 13.6 %
Solanum xanthocarpum : 11.5 % - 13.6 %
Justicia adhatoda : 11.5 % - 13.6 % Acacia arabica : 11.5 % - 13.6 %
Zingiber officinalis : 3.6 % - 4.94%
Syzygium aromaticum bud : 3.6 % - 4.94 %
Curcuma longa : 3.6 % - 4.94 %
Holarrhena antidysentercia : 3.6 % - 4.94 % Enicostemma littorale : 2.22 % - 3.3 %
Calotropis procera : 2.22 % - 3.3 %
Piper longum : 2.22 % - 3.3 %
Piper nigrum : 8.2 % - 7.8 %
Elettaaria Cardamomum : 0.06 % - 0. 19 % - extracting the said herbs collectively with food grade alcohol,
- filtering the extract,
- condensing the said formulation and drying,
- powdering the dried formulation, sieving, and packing in four capsules to be consumed on a single day.
8. A process as claimed in claim 7 wherein said filtration is carried out through cloth followed by Whatman filter paper (no. 1) by applying vacuum pressure.
9. A process as claimed in claim 7 wherein said condensation is carried out by using Rotovac vacuum pump at 650 mm pressure and at temperature 45 °C.
10. A process as claimed in claim 7 wherein said extraction of herbs is carried out for a minimum period of 18 hours.
PCT/IN2002/000041 2001-12-31 2002-03-12 Polyherbal composition for the treatment of bronchial asthma and the process Ceased WO2003055558A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002246307A AU2002246307A1 (en) 2001-12-31 2002-03-12 Polyherbal composition for the treatment of bronchial asthma and the process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1061CH2001 2001-12-31
IN1061/MAS/2001 2001-12-31

Publications (1)

Publication Number Publication Date
WO2003055558A1 true WO2003055558A1 (en) 2003-07-10

Family

ID=11097017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2002/000041 Ceased WO2003055558A1 (en) 2001-12-31 2002-03-12 Polyherbal composition for the treatment of bronchial asthma and the process

Country Status (2)

Country Link
AU (1) AU2002246307A1 (en)
WO (1) WO2003055558A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106622A (en) * 2014-10-16 2017-08-29 同和药品株式会社 The composition of extract or position containing justicia platymiscium
US11534471B2 (en) 2017-09-21 2022-12-27 Dana-Farber Cancer Institute, Inc. Isolation, preservation, compositions and uses of extracts from justicia plants
WO2024003946A1 (en) 2022-06-30 2024-01-04 Swasti Veda Private Limited Poly-herbal composition for respiratory illnesses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113328A1 (en) * 2000-03-28 2001-11-15 Dabur Res Foundation Sahibabad New herbal composition for treating gynecological and other related disorders comprises solvent extracted herbal extract and a plant coagulate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113328A1 (en) * 2000-03-28 2001-11-15 Dabur Res Foundation Sahibabad New herbal composition for treating gynecological and other related disorders comprises solvent extracted herbal extract and a plant coagulate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXOTIC NATURALS, XP002217301, Retrieved from the Internet <URL:http://www.exoticnatural.com/appln.htmhttp://www.exoticnatural.com/appln.htm> [retrieved on 20021018] *
JOHN D: "ONE HUNDRED USEFUL RAW DRUGS OF THE KANI TRIBES OF TRIVANDRUM FOREST DIVISION, KERALA, INDIA", INTERNATIONAL JOURNAL OF CRUDE DRUG RESEARCH, LISSE, NL, vol. 22, no. 1, March 1984 (1984-03-01), pages 17 - 39, XP008007658, ISSN: 0167-7314 *
SZELENYI I ET AL: "HERBAL REMEDIES FOR ASTHMA TREATMENT: BETWEEN MYTH AND REALITY", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 38, no. 4, April 2002 (2002-04-01), pages 265 - 303, XP008007606, ISSN: 0025-7656 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106622A (en) * 2014-10-16 2017-08-29 同和药品株式会社 The composition of extract or position containing justicia platymiscium
EP3207935A4 (en) * 2014-10-16 2018-05-16 Dong Wha Pharm. Co. Ltd. Composition containing extract or fraction of genus justicia plant
US10688143B2 (en) 2014-10-16 2020-06-23 Dong Wha Pharm. Co., Ltd. Composition containing extract or fraction of genus Justicia plant
US11534471B2 (en) 2017-09-21 2022-12-27 Dana-Farber Cancer Institute, Inc. Isolation, preservation, compositions and uses of extracts from justicia plants
WO2024003946A1 (en) 2022-06-30 2024-01-04 Swasti Veda Private Limited Poly-herbal composition for respiratory illnesses

Also Published As

Publication number Publication date
AU2002246307A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
B. Aggarwal et al. Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases:“reverse pharmacology” and “bedside to bench” approach
Meena et al. Plants-herbal wealth as a potential source of ayurvedic drugs
US8163312B2 (en) Herbal formulation for prevention and treatment of diabetes and associated complications
Kunnumakkara et al. Traditional uses of spices: an overview
Selvam Inventory of vegetable crude drug samples housed in botanical survey of India, Howrah
US20110318438A1 (en) Pharmacologically effective composition of herbs for treatment on symptoms of influenza and colds
Ho et al. Traditional practice, bioactivities and commercialization potential of Elephantopus scaber Linn
Rahman et al. Ethno-botanical Study at the Village Pondit Para under Palash Upazila of Narsingdi District, Bangladesh
Pandey et al. Ethnopharmacological reports on herbs used in the management of tuberculosis
CN104138529B (en) A kind of antilipemic Chinese herbal medicine preparation and preparation method thereof
Gautam et al. Tinospora cordifolia: A Successful Story from Botanical background to Pharmaceutical Product
US20060193928A1 (en) Novel herbal compositions and process for preparation thereof
Musthaba et al. Patented herbal formulations and their therapeutic applications
CN101837053A (en) Chinese medicinal composition and preparation for loosening bowel and relieving constipation and preparation method thereof
WO2022028085A1 (en) Spray for treating cervical spondylosis and preparation method therefor
RU2257221C1 (en) Helminthicide species
WO2003055558A1 (en) Polyherbal composition for the treatment of bronchial asthma and the process
CN111991519A (en) Tibetan medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof
Sharma MEDICAL ETHNOBOTANY IN THE svALIK RANGE OF THE HIMALAYAs
Shinde et al. Pharmaceutical study of Vasa (Adhatoda vasica Linn.). With special reference to its different dosage forms
CN112057535B (en) Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia
Kushwaha et al. Standardization of some ayurvedic formulation used in Covid-19
CN1202852C (en) Traditional Chinese medicine for treating wind-cold type of common cold and preparation process thereof
CN108567878B (en) A kind of traditional Chinese medicine composition for preventing and treating fungal skin diseases
CN114533835B (en) A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP